SCHEMBL27889653

SCHEMBL27889653

CCCC(=O)ONC(=O)c1cccnc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HDAC1 Q13547 2/20 0.53
▸ HDAC3 O15379 1/20 0.53
▸ HDAC2 Q92769 1/20 0.53
▸ HDAC6 Q9UBN7 1/20 0.51
▸ THRB P10828 1/20 0.51
▸ ALDH1A1 P00352 4/20 0.50
▸ RAB9A P51151 3/20 0.50
▸ NPC1 O15118 2/20 0.50
▸ SMN1; SMN2 Q16637 2/20 0.50
▸ MEN1 O00255 2/20 0.50
▸ KMT2A Q03164 2/20 0.50
▸ NPSR1 Q6W5P4 2/20 0.49
▸ TP53 P04637 2/20 0.49
▸ LMNA P02545 3/20 0.49
▸ GAA P10253 2/20 0.49
▸ CYP1A2 P05177 1/20 0.49
▸ CYP3A4 P08684 1/20 0.49
▸ KDM4E B2RXH2 1/20 0.49
▸ L3MBTL1 Q9Y468 1/20 0.49
▸ MAPT P10636 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27873273 0.92 HDAC1 (0.58) HDAC1HDAC3HDAC2HDAC6THRB
SCHEMBL27889580 0.88 HDAC1 (0.54) HDAC1HDAC3HDAC2HDAC6THRB
SCHEMBL21082071 0.88 HDAC1 (0.54) HDAC1HDAC3HDAC2HDAC6THRB
SCHEMBL21793728 0.82 TBXAS1 (0.53) —
SCHEMBL6886046 0.82 ALDH1A1 (0.58) HDAC1HDAC3HDAC2HDAC6ALDH1A1
SCHEMBL21082067 0.81 KMT2A (0.58) HDAC1HDAC3HDAC2HDAC6THRB
SCHEMBL9565915 0.79 ALDH1A1 (0.59) HDAC1HDAC3HDAC2HDAC6THRB
SCHEMBL27873274 0.78 ALDH1A1 (0.53) HDAC1HDAC3HDAC2HDAC6THRB
SCHEMBL23069546 0.78 L3MBTL1 (0.60) HDAC1HDAC3HDAC2THRBALDH1A1
SCHEMBL23852218 0.77 ALDH1A1 (0.58) HDAC1HDAC3HDAC2ALDH1A1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102712595-B Novel compositions for reducing A beta 42 production and their use in treating alzheimer's disease (AD) KAREUS THERAPEUTTICS SA 2015-04-22 — — CN disclosed
CN-102712595-A Novel compositions for reducing A beta 42 production and their use in treating alzheimer's disease (AD) KAREUS THERAPEUTTICS SA 2012-10-03 — — CN disclosed
Send feedback